Pharmacogenomic research has indicated that SLCO1B1*5 can reduce hepatic uptake and increase statin concentrations, leading to an increased risk of simvastatin-induced myopathy (Link et al., 2008; Voora et al., 2009). The gene discussed is SLCO1B1; the disease is myopathy.